RU2173997C2 - Фармацевтические препараты замедленного высвобождения, содержащие мизоластин - Google Patents

Фармацевтические препараты замедленного высвобождения, содержащие мизоластин Download PDF

Info

Publication number
RU2173997C2
RU2173997C2 RU98118019/14A RU98118019A RU2173997C2 RU 2173997 C2 RU2173997 C2 RU 2173997C2 RU 98118019/14 A RU98118019/14 A RU 98118019/14A RU 98118019 A RU98118019 A RU 98118019A RU 2173997 C2 RU2173997 C2 RU 2173997C2
Authority
RU
Russia
Prior art keywords
misolastine
pharmaceutical preparation
preparation according
organic acid
tartaric acid
Prior art date
Application number
RU98118019/14A
Other languages
English (en)
Russian (ru)
Other versions
RU98118019A (ru
Inventor
Маривонн ШАРЬЕ (FR)
Маривонн Шарье
Гэрет ЛЮИС (FR)
Гэрет Люис
Жан МОНТЕЛЬ (FR)
Жан Монтель
Original Assignee
Санофи-Синтелябо
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Синтелябо filed Critical Санофи-Синтелябо
Publication of RU98118019A publication Critical patent/RU98118019A/ru
Application granted granted Critical
Publication of RU2173997C2 publication Critical patent/RU2173997C2/ru

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU98118019/14A 1996-03-04 1997-02-28 Фармацевтические препараты замедленного высвобождения, содержащие мизоластин RU2173997C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9602662A FR2745500B1 (fr) 1996-03-04 1996-03-04 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
FR96/02662 1996-03-04

Publications (2)

Publication Number Publication Date
RU98118019A RU98118019A (ru) 2000-07-20
RU2173997C2 true RU2173997C2 (ru) 2001-09-27

Family

ID=9489799

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98118019/14A RU2173997C2 (ru) 1996-03-04 1997-02-28 Фармацевтические препараты замедленного высвобождения, содержащие мизоластин

Country Status (35)

Country Link
US (2) US6165507A (US06373033-20020416-M00035.png)
EP (1) EP0906101B1 (US06373033-20020416-M00035.png)
JP (2) JP2000512617A (US06373033-20020416-M00035.png)
KR (1) KR100369888B1 (US06373033-20020416-M00035.png)
CN (1) CN1112929C (US06373033-20020416-M00035.png)
AR (1) AR006082A1 (US06373033-20020416-M00035.png)
AT (1) ATE219365T1 (US06373033-20020416-M00035.png)
AU (1) AU725494B2 (US06373033-20020416-M00035.png)
BG (1) BG63451B1 (US06373033-20020416-M00035.png)
BR (1) BR9707827A (US06373033-20020416-M00035.png)
CA (1) CA2247405C (US06373033-20020416-M00035.png)
CO (1) CO4780020A1 (US06373033-20020416-M00035.png)
CY (1) CY2293B1 (US06373033-20020416-M00035.png)
CZ (1) CZ291418B6 (US06373033-20020416-M00035.png)
DE (1) DE69713505T2 (US06373033-20020416-M00035.png)
DK (1) DK0906101T3 (US06373033-20020416-M00035.png)
EE (1) EE03511B1 (US06373033-20020416-M00035.png)
ES (1) ES2177942T3 (US06373033-20020416-M00035.png)
FR (1) FR2745500B1 (US06373033-20020416-M00035.png)
HK (1) HK1017999A1 (US06373033-20020416-M00035.png)
HU (1) HU227472B1 (US06373033-20020416-M00035.png)
IL (1) IL126050A (US06373033-20020416-M00035.png)
IN (1) IN187739B (US06373033-20020416-M00035.png)
NO (1) NO315841B1 (US06373033-20020416-M00035.png)
NZ (1) NZ331947A (US06373033-20020416-M00035.png)
OA (1) OA10854A (US06373033-20020416-M00035.png)
PL (1) PL189813B1 (US06373033-20020416-M00035.png)
PT (1) PT906101E (US06373033-20020416-M00035.png)
RU (1) RU2173997C2 (US06373033-20020416-M00035.png)
SK (1) SK282112B6 (US06373033-20020416-M00035.png)
TR (1) TR199801574T2 (US06373033-20020416-M00035.png)
TW (1) TW491711B (US06373033-20020416-M00035.png)
UA (1) UA49004C2 (US06373033-20020416-M00035.png)
WO (1) WO1997032584A1 (US06373033-20020416-M00035.png)
ZA (1) ZA971830B (US06373033-20020416-M00035.png)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002087960A (ja) * 2000-07-14 2002-03-27 Toyama Chem Co Ltd 徐放性錠剤
DK1322158T3 (da) * 2000-10-02 2012-11-19 Usv Ltd Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
NZ542176A (en) * 2003-03-04 2007-12-21 Nostrum Pharmaceuticals Inc Control release formulation containing a hydrophobic material as the sustained release agent
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
EP2564833B1 (en) 2008-07-28 2017-12-20 Takeda Pharmaceutical Company Limited Photostabilized pharmaceutical composition
JP5744412B2 (ja) * 2010-03-26 2015-07-08 テバ製薬株式会社 フロセミド製剤
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
JPS62283926A (ja) * 1986-06-02 1987-12-09 Nippon Chemiphar Co Ltd 塩酸ニカルジピン持続性組成物
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
JP3195391B2 (ja) * 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤

Also Published As

Publication number Publication date
HUP9902458A2 (hu) 2000-05-28
ZA971830B (en) 1997-09-04
NO315841B1 (no) 2003-11-03
SK121098A3 (en) 1999-01-11
JP2007182451A (ja) 2007-07-19
NO984035D0 (no) 1998-09-02
TR199801574T2 (xx) 1998-11-23
IL126050A0 (en) 1999-05-09
PL328763A1 (en) 1999-02-15
ATE219365T1 (de) 2002-07-15
FR2745500A1 (fr) 1997-09-05
CA2247405A1 (en) 1997-09-12
NO984035L (no) 1998-10-22
KR100369888B1 (ko) 2003-05-17
BG102692A (en) 1999-04-30
EP0906101A1 (fr) 1999-04-07
EP0906101B1 (fr) 2002-06-19
DE69713505D1 (de) 2002-07-25
HUP9902458A3 (en) 2002-11-28
CO4780020A1 (es) 1999-05-26
WO1997032584A1 (fr) 1997-09-12
CN1112929C (zh) 2003-07-02
BG63451B1 (bg) 2002-02-28
CY2293B1 (en) 2003-07-04
HK1017999A1 (en) 1999-12-10
PT906101E (pt) 2002-09-30
HU227472B1 (en) 2011-07-28
DE69713505T2 (de) 2003-02-13
EE9800275A (et) 1999-02-15
PL189813B1 (pl) 2005-09-30
CZ279198A3 (cs) 1999-01-13
BR9707827A (pt) 1999-07-27
CA2247405C (en) 2004-04-20
US20050202089A1 (en) 2005-09-15
NZ331947A (en) 2000-03-27
OA10854A (fr) 2003-02-05
TW491711B (en) 2002-06-21
FR2745500B1 (fr) 1998-04-03
IN187739B (US06373033-20020416-M00035.png) 2002-06-15
IL126050A (en) 2004-05-12
ES2177942T3 (es) 2002-12-16
UA49004C2 (uk) 2002-09-16
US6165507A (en) 2000-12-26
AU1930097A (en) 1997-09-22
JP2000512617A (ja) 2000-09-26
CN1212624A (zh) 1999-03-31
SK282112B6 (sk) 2001-11-06
EE03511B1 (et) 2001-10-15
AR006082A1 (es) 1999-08-11
DK0906101T3 (da) 2002-10-14
AU725494B2 (en) 2000-10-12
KR19990087387A (ko) 1999-12-27
CZ291418B6 (cs) 2003-03-12

Similar Documents

Publication Publication Date Title
US6641840B2 (en) Sustained release formulations for growth hormone secretagogues
CN100402021C (zh) 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)苯酚并能提供活性成分的延迟释放的药物
US7741374B1 (en) Methods of use of fenofibric acid
BG64168B1 (bg) Бързоразтворима таблета на галантамин хидробромид
JPH05246844A (ja) HMG−CoAリダクターゼ禁止剤化合物を含んでなる安定化された製薬学的組成物
JP2012254993A (ja) バルデナフィルを含有する制御放出製剤
JP2003503340A (ja) 短時間型催眠薬またはその塩からなる二重持効性剤形
JP2007182451A (ja) ミゾラスチンを含有する徐放性医薬製剤
AU2013240846A1 (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
RU2672573C2 (ru) Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин
RU2286784C2 (ru) Таблетка, содержащая цетиризин и псевдоэфедрин
US6228395B1 (en) Sustained-release microgranules containing Diltiazem as the active principle
US7014867B2 (en) Tablet comprising cetirizine and pseudoephedrine
CN115192572A (zh) 布立西坦药剂、其制备方法和应用
EP2812074B1 (en) Modified release formulations of viloxazine
JP2002538197A (ja) ベタヒスチンの徐放性組成物
ZA200401547B (en) A new extended release oral dosage form.
RU2287328C2 (ru) Твердый препарат с высоким всасыванием

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner